Patents Issued in May 12, 2020
-
Patent number: 10647724Abstract: The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.Type: GrantFiled: February 3, 2017Date of Patent: May 12, 2020Assignee: INVENTISBIO INC.Inventors: Xing Dai, Yaolin Wang
-
Patent number: 10647725Abstract: 2-Aminothiophene derivatives, uses of the same, and methods of making the same, are described.Type: GrantFiled: April 21, 2017Date of Patent: May 12, 2020Assignees: The University of Toledo, Colorado State University Research FoundationInventors: Steven Sucheck, Sandeep Thanna, Richard Slayden
-
Patent number: 10647726Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.Type: GrantFiled: November 6, 2018Date of Patent: May 12, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Wasmuth, Donald W. Landry
-
Patent number: 10647727Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: June 20, 2016Date of Patent: May 12, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Gregori J. Morriello, Lehua Chang, Ashley Forster, Richard Berger, Kausik K. Nanda, William D. Shipe
-
Patent number: 10647728Abstract: The present invention relates to the preparation of a compound of formula VI:Type: GrantFiled: December 3, 2018Date of Patent: May 12, 2020Assignee: ViiV Healthcare CompanyInventors: Steven N. Goodman, Huan Wang, Douglas Mans, Matthew Kowalski
-
Patent number: 10647729Abstract: The present invention relates to novel crystalline forms of dolutegravir, process for its preparation and pharmaceutical composition comprising them.Type: GrantFiled: January 14, 2020Date of Patent: May 12, 2020Assignee: Laurus Labs LimitedInventors: Ram Thaimattam, Rajesh Edupuganti, Venkata Sunil Kumar Indukuri, Srihari Raju Kalidindi, Satyanarayana Chava
-
Patent number: 10647730Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.Type: GrantFiled: February 20, 2018Date of Patent: May 12, 2020Assignee: Array BioPharma Inc.Inventors: Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Jeongbeob Seo, Hong-Woon Yang, Qian Zhao
-
Patent number: 10647731Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.Type: GrantFiled: April 25, 2018Date of Patent: May 12, 2020Assignee: Genentech, Inc.Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
-
Patent number: 10647732Abstract: PDI derivatives useful as opto-electronically active materials or for the synthesis of such materials. Certain compounds herein function as efficient electron acceptors and are useful as electron active components of electronic devices.Type: GrantFiled: January 9, 2018Date of Patent: May 12, 2020Assignee: UTI Limited PartnershipInventors: Gregory C. Welch, Arthur D. Hendsbee
-
Patent number: 10647733Abstract: Metal-organic framework (MOFs) compositions based on nitrogen donor-based organic bridging ligands, including ligands based on 1,3-diketimine (NacNac), bipyridines and salicylaldimine, were synthesized and then post-synthetically metalated with metal precursors, such as complexes of first row transition metals. Metal complexes of the organic bridging ligands could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.Type: GrantFiled: March 30, 2015Date of Patent: May 12, 2020Assignee: The University of ChicagoInventors: Wenbin Lin, Kuntal Manna, Teng Zhang
-
Patent number: 10647734Abstract: A method for dehydrocoupling silanes and amines. The method comprises contacting: (a) an aliphatic amine; (b) a silane; and (c) a catalyst which is ZnX2, wherein X is alkyl, chloride, bromide, iodide, trifluoromethanesulfonate, bis(trifluoromethane)sulfonamide, tosylate, methanesulfonate or O3S(CF2)XCF3 wherein x is an integer from 1 to 10.Type: GrantFiled: November 29, 2017Date of Patent: May 12, 2020Assignee: Dow Corning CorporationInventor: Brian D. Rekken
-
Patent number: 10647735Abstract: A method of preparing a tuned metal complex including the use of band gap tuning to change the light absorbing or light emitting properties of a metal complex. In one aspect, band gap tuning includes changing the energy gap between the conduction band and the valence band of a metal complex with a guest molecule.Type: GrantFiled: July 12, 2018Date of Patent: May 12, 2020Assignee: University of New BrunswickInventors: Barry A Blight, Barbora Balónová
-
Patent number: 10647736Abstract: A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.Type: GrantFiled: May 16, 2018Date of Patent: May 12, 2020Assignee: Akeso Biomedical, Inc.Inventors: Dlawer Ala'Aldeen, Jafar Mahdavi, Panos Soultanas
-
Patent number: 10647737Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.Type: GrantFiled: July 10, 2015Date of Patent: May 12, 2020Assignee: National Research Council of CanadaInventors: Dennis M. Whitfield, G. Dennis Sprott, Lakshmi Krishnan
-
Patent number: 10647738Abstract: The present invention relates to a xylene-based amphiphilic compound, a method for preparing the same, and a method for extracting, solubilizing, stabilizing or crystallizing a membrane protein using the same. By using the xylene-based compound according to the present invention, a membrane protein may be stably stored in an aqueous solution for a long time, and may be applied in functional and structural analyses. The structural and functional analysis of the membrane protein is one of the fields of highest interest in biology and chemistry, and the xylene-based compound according to the present invention can be applied in research on protein structure that is closely related to development of a new drug.Type: GrantFiled: April 15, 2016Date of Patent: May 12, 2020Assignee: Industry-University Cooperation FoundationInventors: Pil Seok Chae, Kyung Ho Cho
-
Patent number: 10647739Abstract: The invention relates to a method for producing derivatives of O-?-glucosylated flavonoid, comprising at least one step of incubating a glucansucrase with a flavonoid and at least one sucrose, the flavonoid being a flavonoid which is monohydroxylated or hydroxylated in a non-vicinal manner on the B cycle. The invention also relates to novel O-?-glucosylated flavonoid derivatives, and to the use thereof.Type: GrantFiled: March 24, 2015Date of Patent: May 12, 2020Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, INSTITUTE NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Sandrine Morel, Isabelle Andre, Yoan Brison, Emmanuelle Cambon, Yannick Malbert, Denis Pompon, Magali Remaud-Simeon, Philippe Urban
-
Patent number: 10647740Abstract: Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.Type: GrantFiled: December 21, 2017Date of Patent: May 12, 2020Assignee: Enzo Life Science, Inc.Inventors: Jack Coleman, Elazar Rabbani, Jannis Stavrianopoulos, Praveen Pande
-
Patent number: 10647741Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: June 24, 2019Date of Patent: May 12, 2020Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 10647742Abstract: Provided is a method for solid phase synthesis of Etelcalcetide, comprising synthesizing Etelcalcetide backbone peptide resin, removing the side chain protecting group of Cys in the peptide chain, and then activating the sulfydryl group of the Cys side chain on the peptide resin with 2,2?-dithiodipyridine and constructing a disulfide bond with L-Cys, such that a crude Etelcalcetide peptide is obtained by cleaving. The method does not require undergoing multi-step purification, the yield and purity of the obtained crude peptide are relatively high, and the total yield of the refined peptide after purification is greatly increased.Type: GrantFiled: December 20, 2016Date of Patent: May 12, 2020Assignee: HYBIO PHARMACEUTICAL CO., LTD.Inventors: Yonghan Chen, Pengcheng Mi, Anjin Tao, Jiancheng Yuan
-
Patent number: 10647743Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.Type: GrantFiled: March 6, 2013Date of Patent: May 12, 2020Assignee: Wisconsin Alumni Research FoundationInventors: William Seth Horne, Samuel H. Gellman, Lisa M. Johnson
-
Patent number: 10647744Abstract: Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.Type: GrantFiled: August 30, 2016Date of Patent: May 12, 2020Assignee: Onyx Therapeutics, Inc.Inventors: Dustin McMinn, Henry Johnson, Simeon Bowers, David C. Moebius
-
Patent number: 10647745Abstract: The present invention provides a compound (I) for treating sequelae of ischemic cerebral stroke: H—(NH—CHR1—CO)—(NH—CHR2—CO)—(NH—CHR3—CO)—(NH—CHR4—CO)—(NH—CHR5—CO)—(NH—CHR6—CO)—(NH—CHR7—CO)—OH??(I) or a pharmaceutically acceptable salt thereof, wherein R1-R7 are defined herein. The present invention also provides a pharmaceutical composition comprising said compound and use of the same in the manufacture of a medicament for treating sequelae of ischemic cerebral stroke. The compound and pharmaceutical composition according to the present invention have good pharmacological activities so that they are able to improve significantly the symptom of sequelae of ischemic cerebral stroke.Type: GrantFiled: August 9, 2018Date of Patent: May 12, 2020Inventor: Jingyi Wang
-
Patent number: 10647746Abstract: Described are design and generation of a set of novel cyclic lipopeptides as potential antibacterial agents. New daptomycin analogues are generated by chemical synthesis, which makes introduction of an unnatural amino acid and any modification into daptomycin possible.Type: GrantFiled: April 8, 2016Date of Patent: May 12, 2020Assignee: Versitech LimitedInventor: Xuechen Li
-
Patent number: 10647747Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.Type: GrantFiled: December 15, 2017Date of Patent: May 12, 2020Assignee: S&T GLOBAL INC.Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
-
Patent number: 10647748Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.Type: GrantFiled: October 31, 2018Date of Patent: May 12, 2020Assignee: The Scripps Research InstituteInventors: Leopold Kong, Ian A. Wilson, Natalia De Val, Andrew B. Ward, Dennis Burton, Linling He, Jiang Zhu
-
Patent number: 10647749Abstract: The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.Type: GrantFiled: April 23, 2019Date of Patent: May 12, 2020Assignees: Syddansk Universitet, Aarhus UniversitetInventors: Anders Boysen, Jakob Møller-Jensen, Giuseppe Palmisano, Martin Røssel Larsen
-
Patent number: 10647750Abstract: Engineered clostridial toxins comprising an amino acid modification that increases the isoelectric point of the engineered clostridial toxin to a value that is at least 0.2 pI units higher than the isoelectric point of an otherwise identical clostridial toxin lacking the modification, wherein the modification is not located in the clostridial toxin binding domain (HC domain).Type: GrantFiled: January 9, 2015Date of Patent: May 12, 2020Assignee: IPSEN BIOINNOVATION LIMITEDInventors: Dina Brady Anderson, Gavin Stephen Hackett, Sai Man Liu
-
Patent number: 10647751Abstract: An adeno-associated viral (AAV) vector containing an expression construct, wherein: the expression construct comprises a nucleic acid sequence which encodes a microdystrophin (MD); and the nucleic acid sequence encoding the MD has a size of at least 4.1 kb.Type: GrantFiled: May 9, 2016Date of Patent: May 12, 2020Assignee: ROYAL HOLLOWAY & BEDFORD NEW COLLEGEInventor: George Dickson
-
Patent number: 10647752Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.Type: GrantFiled: September 21, 2016Date of Patent: May 12, 2020Assignees: INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at MetierInventors: Zakia Belaid-Choucair, Olivier Hermine, Matthieu Montes, Carmen Garrido-Fleury, Renaud Seigneuric, Guillaume Marcion
-
Patent number: 10647753Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.Type: GrantFiled: May 25, 2018Date of Patent: May 12, 2020Assignee: HANMI PHARM. CO., LTD.Inventors: Jin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon
-
Patent number: 10647754Abstract: The invention provides a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the single domain CD4 and one or more fusion partners. A nucleic acid encoding the polypeptide or fusion protein, as well as compositions or cells comprising the polypeptide, fusion protein, or nucleic acid also are provided.Type: GrantFiled: October 16, 2017Date of Patent: May 12, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Weizao Chen, Prabakaran Ponraj
-
Patent number: 10647755Abstract: The present disclosure provides light-sensitive protein hydrogels, and methods of their use thereof. The hydrogels can be used for cell encapsulation, culturing, and selective release under appropriate light conditions.Type: GrantFiled: May 9, 2018Date of Patent: May 12, 2020Assignee: The Hong Kong University of Science and TechnologyInventors: Fei Sun, Ri Wang
-
Patent number: 10647756Abstract: Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.Type: GrantFiled: May 16, 2016Date of Patent: May 12, 2020Assignee: Pfizer Inc.Inventors: William James Jonathan Finlay, Lioudmila Tchistiakova, Eric M. Bennett
-
Patent number: 10647757Abstract: The present disclosure enables methods of identifying the VH and VL class pairs in the human immune repertoire, determining the VH and VL class pairs that are most prevalent and those having favorable biophysical properties. More specifically, the collections of the present disclosure comprise the most prevalent and/or preferred VH and VL class pairings with highly diversified CDRs.Type: GrantFiled: March 3, 2017Date of Patent: May 12, 2020Assignee: MORPHOSYS AGInventors: Markus Enzelberger, Stefanie Urlinger, Thomas Tiller, Josef Prassler, Tanja Herrmann
-
Patent number: 10647758Abstract: A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5? and 3? ITRs flank the expression cassettes and regulatory sequences.Type: GrantFiled: July 2, 2019Date of Patent: May 12, 2020Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: James M. Wilson, Anna Tretiakova
-
Patent number: 10647759Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.Type: GrantFiled: April 16, 2018Date of Patent: May 12, 2020Assignee: Eli Lilly and CompanyInventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
-
Patent number: 10647760Abstract: The invention relates to the diagnosis and treatment of diseases, including inflammatory disorders, proliferative disorders and autoimmune diseases. The invention provides, and involves the use of, antibody molecules that bind: i) lysozyme, ii) neutrophil elastase, iii) tissue inhibitor of metalloproteinase-1 (TIMP-1), or iv) the D domain of Tenascin-C. The invention also relates to the use of antibody molecules that bind v) the IIICS isoform of fibronectin, vi) the Extra Domain-B (ED-B) of fibronectin, vii) matrix-metalloproteinase 3 (MMP3), or viii) the A1 domain of tenascin-C in the diagnosis and treatment of inflammatory disorders such as inflammatory bowel disease.Type: GrantFiled: December 9, 2016Date of Patent: May 12, 2020Assignee: PHILOGEN S.P.A.Inventors: Sarah Wulhfard, Alessandra Villa, Catherine Pemberton Ross, Francesca Pretto, Filippa Fleetwood
-
Patent number: 10647761Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.Type: GrantFiled: March 20, 2019Date of Patent: May 12, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
-
Patent number: 10647762Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.Type: GrantFiled: April 1, 2019Date of Patent: May 12, 2020Assignee: H. Lundbeck A/SInventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
-
Patent number: 10647763Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.Type: GrantFiled: June 17, 2019Date of Patent: May 12, 2020Assignee: H. Lundbeck A/SInventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
-
Patent number: 10647764Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.Type: GrantFiled: June 17, 2019Date of Patent: May 12, 2020Assignee: H. Lundbeck A/SInventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
-
Patent number: 10647765Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH??(formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.Type: GrantFiled: March 16, 2018Date of Patent: May 12, 2020Assignee: HOFFMANN-LA ROCHE INC.Inventors: Herbert Andres, David Casagolda Vallribera, Hartmut Duefel, Michael Gerg, Christian Scholz, Michael Schraeml
-
Patent number: 10647766Abstract: Anti-CXCL12 antibody molecules and their uses are disclosed, and in particular anti-CXCL12 antibody molecules that are capable of inhibiting a biological activity of CXCL12 in vitro and in vivo and their use for treating CXCL12-mediated disease.Type: GrantFiled: December 11, 2015Date of Patent: May 12, 2020Assignee: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Frances Rosemary Balkwill, John McCafferty, Gerard John Graham, Aneesh Karatt Vellatt, Peter Slavny
-
Patent number: 10647767Abstract: Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also provided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders.Type: GrantFiled: September 18, 2017Date of Patent: May 12, 2020Assignee: I-Mab Biopharma Co., Ltd.Inventors: Zhengyi Wang, Lei Fang, Bingshi Guo, Jingwu Zang
-
Patent number: 10647768Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.Type: GrantFiled: May 29, 2015Date of Patent: May 12, 2020Assignee: MACROGENICS, INC.Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
-
Patent number: 10647769Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.Type: GrantFiled: November 7, 2019Date of Patent: May 12, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
-
Patent number: 10647770Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.Type: GrantFiled: June 9, 2017Date of Patent: May 12, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shiro Shibayama, Masamichi Imai
-
Patent number: 10647771Abstract: The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.Type: GrantFiled: September 20, 2016Date of Patent: May 12, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Jennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
-
Patent number: 10647773Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.Type: GrantFiled: June 28, 2019Date of Patent: May 12, 2020Assignee: GENSUN BIOPHARMA, INC.Inventors: Jackie Sheng, Bo Liu
-
Patent number: 10647774Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.Type: GrantFiled: February 17, 2017Date of Patent: May 12, 2020Assignee: GENMAB B.V.Inventors: Claudine Brigitte Fernande Vermot-Desroches, Olivier Frédéric Subiger, Laurence Françoise Jeanne-Marie Bourdin